Modifi Biosciences Acquired by Merck NEW HAVEN, Conn., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Modifi Biosciences, Inc. (“Modifi Biosciences”), a leader in the development of direct DNA modification enabled cancer therapeutics, today...

Modifi Bio Raises Additional $4.3 Million in Seed Funding NEW HAVEN, Conn., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Modifi Biosciences, a leader in DNA modification as a novel approach to target cancer, today announced the closing of $4.3 million in a second...

Modifi Bio Announces Scientific Advisory Board NEW HAVEN, Conn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Modifi Biosciences, a leader in DNA modification as a novel approach to target cancer, today announced its Scientific Advisory Board, with the...

Modifi Bio Receives $2.4 Million Award from National Cancer Institute to Advance Innovative Precision Oncology Platform NEW HAVEN, Conn., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Modifi Biosciences, a leader in direct DNA modification developing novel cancer therapeutics, has been selected by the National Cancer Institute...

Science Publication First to Describe Modifi Bio’s Novel Approach to Fight Cancer Cells with DNA Modification NEW HAVEN, Conn., July 28, 2022 (GLOBE NEWSWIRE) -- Modifi Biosciences announced today that the journal Science has published a critical study validating the company’s novel oncology platform based...